Emilie Leroy

1.2k citations

19 papers · 650 indexed · h-index 13

Co-authors: Stefan N. Constantinescu C. Pecquet Róbert Královics Jelena D. Milosevic Feenstra William Vainchenker Céline Mouton Ilyas Chachoua Jean‐Philippe Defour
Topics: Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers)Cytokine Signaling Pathways and Interactions (8 papers)Chronic Myeloid Leukemia Treatments (6 papers)
Cited by: Genetics Hematology Rheumatology
Journals: Journal of Biological Chemistry The EMBO Journal Blood
Partner nations: Belgium United States France

In The Last Decade

Emilie Leroy

19 papers receiving 645 citations

Peers

Countries citing papers authored by Emilie Leroy

Since Specialization

Citations

This map shows the geographic impact of Emilie Leroy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emilie Leroy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emilie Leroy more than expected).

Fields of papers citing papers by Emilie Leroy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emilie Leroy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emilie Leroy. The network helps show where Emilie Leroy may publish in the future.

Co-authorship network of co-authors of Emilie Leroy

This figure shows the co-authorship network connecting the top 25 collaborators of Emilie Leroy. A scholar is included among the top collaborators of Emilie Leroy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emilie Leroy. Emilie Leroy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers 2023 ·eLife ·Jean‐Philippe Defour,Emilie Leroy,(unknown),Thomas Balligand,(unknown),Ian Brett,Nicolas Papadopoulos,Céline Mouton,(unknown),C. Pecquet,Judith Staerk,Steven O. Smith,Stefan N. Constantinescu	3
2	MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491 2020 ·Blood ·(unknown),Serge Carillo,(unknown),Bruno Cassinat,Jean‐Marc Zini,Emilie Leroy,Leila N. Varghese,Ilyas Chachoua,Jean‐Philippe Defour,Steven O. Smith,Stefan N. Constantinescu	8
3	Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling 2019 ·Journal of Allergy and Clinical Immunology ·Emilie Leroy,Thomas Balligand,C. Pecquet,Céline Mouton,Didier Colau,Andrew K. Shiau,Alexandra Dusa,Stefan N. Constantinescu	18
4	JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera 2019 ·Blood ·Ami B. Patel,(unknown),Emilie Leroy,Soo Jin Kim,Anthony D. Pomicter,(unknown),(unknown),Dongqing Yan,Jonathan M. Ahmann,Archana M. Agarwal,Phillip M. Clair,(unknown),Jonathan Lambert,(unknown),Gerald J. Gleich,Nicholas C.P. Cross,Stefan N. Constantinescu,Thomas O’Hare,Josef T. Prchal,Michael W. Deininger	21
5	PS1441 A NOVEL ACTIVATING TPOR MUTATION IN ESSENTIAL THROMBOCYTOPENIA POINTS TO AN ACTIVATING EFFECT OF TRYPTOPHAN AND AROMATICS AT THE OUTSET OF THE TRANSMEMBRANE DOMAIN 2019 ·HemaSphere ·(unknown),Serge Carillo,(unknown),Emilie Leroy,Jean‐Philippe Defour,Steven O. Smith,Stefan N. Constantinescu	1
6	JAK2 V617F Dimerizes Homodimeric Cytokine Receptors Cytosolic Domains By Requiring Pseudokinase Domain Residues That Promote JAK2 Dimerization and Oncogenic Activity 2018 ·Blood ·Emilie Leroy,Thomas Balligand,Stefan N. Constantinescu	1
7	Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition 2017 ·Leukemia ·Emilie Leroy,Stefan N. Constantinescu	64
8	Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL 2017 ·Blood ·Sandrine Degryse,Simon Bornschein,Charles E. de Bock,Emilie Leroy,Marlies Vanden Bempt,Sofie Demeyer,Kris Jacobs,Ellen Geerdens,Olga Gielen,Jean Soulier,Christine J. Harrison,Stefan N. Constantinescu,Jan Cools	30
9	Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia 2016 ·Blood ·(unknown),Monika Horváthová,C. Pecquet,Jana Kučerová,Dagmar Pospı́šilová,Emilie Leroy,(unknown),Jelena D. Milosevic Feenstra,Fiorella Schischlik,Róbert Královics,Stefan N. Constantinescu,Vladimír Divoký	39
10	Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix 2016 ·Biochemical Journal ·Emilie Leroy,Alexandra Dusa,Didier Colau,Amir Motamedi,Xavier Cahu,Céline Mouton,Lily Huang,Andrew K. Shiau,Stefan N. Constantinescu	33
11	His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin Receptor 2015 ·Journal of Biological Chemistry ·Emilie Leroy,Jean‐Philippe Defour,Takeshi Sato,(unknown),Vitalina Gryshkova,(unknown),Judith Staerk,Stefan N. Constantinescu,Steven O. Smith	23
12	Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms 2015 ·Blood ·Jelena D. Milosevic Feenstra,Harini Nivarthi,Heinz Gisslinger,Emilie Leroy,Elisa Rumi,Ilyas Chachoua,Klaudia Bagienski,Blanka Kubešová,Daniela Pietra,Bettina Gisslinger,Chiara Milanesi,Roland Jäger,Doris Chen,Tiina Berg,Martin Schalling,Michael Schuster,Christoph Bock,Stefan N. Constantinescu,Mario Cazzola,Róbert Královics	196
13	Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms 2015 ·Blood ·Jelena D. Milosevic Feenstra,(unknown),(unknown),Emilie Leroy,Elisa Rumi,Ilyas Chachoua,Klaudia Bagienski,Blanka Kubešová,Daniela Pietra,Bettina Gisslinger,Roland Jäger,Doris Chen,Tiina Berg,Martin Schalling,Michael Schuster,Christoph Bock,Stefan N. Constantinescu,Mario Cazzola,Róbert Královics	1
14	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors 2014 ·Blood ·Caroline Marty,Cécile Saint‐Martin,C. Pecquet,(unknown),Joseph Saliba,Céline Mouton,Emilie Leroy,Ashot S. Harutyunyan,(unknown),Rémi Favier,Aurélie Toussaint,Éric Solary,Róbert Královics,Stefan N. Constantinescu,A Najman,William Vainchenker,Isabelle Plo,Christine Bellanné‐Chantelot	55
15	JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5 2014 ·Blood ·(unknown),Monika Horváthová,Jana Kučerová,Dagmar Pospı́šilová,Emilie Leroy,Stefan N. Constantinescu,Vladimír Divoký	3
16	Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors 2014 ·Blood ·(unknown),Tekla Hornakova,(unknown),(unknown),Emilie Leroy,Stefan N. Constantinescu,Elisabetta Flex,Marco Tartaglia,Laurent Knoops,Jean‐Christophe Renauld	34
17	Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors 2013 ·Blood ·Caroline Marty,Cécile Saint‐Martin,C. Pecquet,(unknown),Joseph Saliba,Céline Mouton,Emilie Leroy,Ashot S. Harutyunyan,Jean‐François Abgrall,(unknown),Éric Solary,Róbert Královics,Stefan N. Constantinescu,A Najman,William Vainchenker,Isabelle Plo,Christine Bellanné‐Chantelot	41
18	Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers 2013 ·Biochemical Society Transactions ·Stefan N. Constantinescu,Emilie Leroy,Vitalina Gryshkova,C. Pecquet,Alexandra Dusa	15
19	Orientation‐specific signalling by thrombopoietin receptor dimers 2011 ·The EMBO Journal ·Judith Staerk,Jean‐Philippe Defour,C. Pecquet,Emilie Leroy,Hélène Antoine‐Poirel,Ian Brett,(unknown),Steven O. Smith,William Vainchenker,Stefan N. Constantinescu	64

About Emilie Leroy

Emilie Leroy is a scholar working on Genetics, Hematology and Oncology, having authored 19 papers that have together received 650 indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers), Cytokine Signaling Pathways and Interactions (8 papers) and Chronic Myeloid Leukemia Treatments (6 papers). The work is most often cited by research in Genetics (514 citations), Hematology (385 citations) and Rheumatology (150 citations). Emilie Leroy has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Stefan N. Constantinescu, C. Pecquet, Róbert Královics, Jelena D. Milosevic Feenstra, William Vainchenker, Céline Mouton, Ilyas Chachoua, Jean‐Philippe Defour, Heinz Gisslinger and Steven O. Smith. Their work appears in journals such as Journal of Biological Chemistry, The EMBO Journal and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact